Having trouble accessing articles? Reset your cache.

Following promising ASCO readout for AMG 510, Amgen looks to identify more KRAS-mutant patients

After making a strong showing at ASCO with data for its KRAS inhibitor in non-small cell lung cancer patients, Amgen will now look to expand the program's options for finding trial-eligible patients.

Amgen Inc. (NASDAQ:AMGN) reported updated Phase I

Read the full 389 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE